Home
/
NovoCure Ltd
/
Financials
/
Quarterly
NovoCure Ltd — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that NovoCure Ltd filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$167.20M
Oct 30, 2025
Q2
2025
Jun 30, 2025
$158.81M
Jul 24, 2025
Q1
2025
Mar 31, 2025
$154.99M
Apr 24, 2025
Q2
2025
Dec 31, 2024
$605.22M
Jul 24, 2025
Q3
2025
Dec 31, 2024
$605.22M
Oct 30, 2025
Q1
2025
Dec 31, 2024
$605.22M
Apr 24, 2025
Q3
2025
Sep 30, 2024
$155.10M
Oct 30, 2025
Q2
2025
Jun 30, 2024
$150.36M
Jul 24, 2025
Q1
2025
Mar 31, 2024
$138.50M
Apr 24, 2025
Q1
2024
Dec 31, 2023
$509.34M
May 2, 2024
Q3
2024
Dec 31, 2023
$509.34M
Oct 30, 2024
Q2
2024
Dec 31, 2023
$509.34M
Jul 25, 2024
Q3
2024
Sep 30, 2023
$127.32M
Oct 30, 2024
Q2
2024
Jun 30, 2023
$126.05M
Jul 25, 2024
Q1
2024
Mar 31, 2023
$122.18M
May 2, 2024
Q1
2023
Dec 31, 2022
$537.84M
May 4, 2023
Q2
2023
Dec 31, 2022
$537.84M
Jul 27, 2023
Q3
2023
Dec 31, 2022
$537.84M
Oct 26, 2023
Q3
2023
Sep 30, 2022
$131.00M
Oct 26, 2023
Q2
2023
Jun 30, 2022
$140.87M
Jul 27, 2023
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2018
Mar 31, 2018
$52.13M
Apr 26, 2018
Q1
2018
Dec 31, 2017
$177.03M
Apr 26, 2018
Q3
2017
Sep 30, 2017
$50.11M
Oct 26, 2017
Q2
2017
Jun 30, 2017
$38.38M
Jul 27, 2017
Q1
2018
Mar 31, 2017
$34.88M
Apr 26, 2018
Q1
2017
Dec 31, 2016
$82.89M
Apr 27, 2017
Q3
2017
Dec 31, 2016
$82.89M
Oct 26, 2017
Q2
2017
Dec 31, 2016
$82.89M
Jul 27, 2017
Q3
2017
Sep 30, 2016
$21.67M
Oct 26, 2017
Q2
2017
Jun 30, 2016
$17.92M
Jul 27, 2017
Q1
2017
Mar 31, 2016
$13.05M
Apr 27, 2017
Q2
2016
Dec 31, 2015
$33.09M
Jul 28, 2016
Q1
2016
Dec 31, 2015
$33.09M
May 10, 2016
Q3
2016
Dec 31, 2015
$33.09M
Nov 2, 2016
Q3
2016
Sep 30, 2015
$8.95M
Nov 2, 2016
Q2
2016
Jun 30, 2015
$6.54M
Jul 28, 2016
Q1
2016
Mar 31, 2015
$5.21M
May 10, 2016
Q3
2015
Sep 30, 2014
$4.37M
Oct 27, 2015
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($37.27M)
Oct 30, 2025
Q2
2025
Jun 30, 2025
($40.14M)
Jul 24, 2025
Q3
2025
Jun 30, 2025
($40.14M)
Oct 30, 2025
Q3
2025
Mar 31, 2025
($34.32M)
Oct 30, 2025
Q2
2025
Mar 31, 2025
($34.32M)
Jul 24, 2025
Q1
2025
Mar 31, 2025
($34.32M)
Apr 24, 2025
Q2
2025
Dec 31, 2024
($168.63M)
Jul 24, 2025
Q1
2025
Dec 31, 2024
($168.63M)
Apr 24, 2025
Q3
2025
Dec 31, 2024
($168.63M)
Oct 30, 2025
Q3
2025
Sep 30, 2024
($30.57M)
Oct 30, 2025
Q2
2025
Jun 30, 2024
($33.38M)
Jul 24, 2025
Q3
2025
Jun 30, 2024
($33.38M)
Oct 30, 2025
Q3
2025
Mar 31, 2024
($38.76M)
Oct 30, 2025
Q1
2025
Mar 31, 2024
($38.76M)
Apr 24, 2025
Q2
2025
Mar 31, 2024
($38.76M)
Jul 24, 2025
Q2
2024
Dec 31, 2023
($207.04M)
Jul 25, 2024
Q1
2024
Dec 31, 2023
($207.04M)
May 2, 2024
Q3
2024
Dec 31, 2023
($207.04M)
Oct 30, 2024
Q3
2024
Sep 30, 2023
($49.49M)
Oct 30, 2024
Q3
2024
Jun 30, 2023
($57.42M)
Oct 30, 2024
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($36.02M)
Oct 30, 2025
Q2
2025
Jun 30, 2025
($39.52M)
Jul 24, 2025
Q1
2025
Mar 31, 2025
($37.87M)
Apr 24, 2025
Q3
2025
Dec 31, 2024
($170.50M)
Oct 30, 2025
Q2
2025
Dec 31, 2024
($170.50M)
Jul 24, 2025
Q1
2025
Dec 31, 2024
($170.50M)
Apr 24, 2025
Q3
2025
Sep 30, 2024
($32.09M)
Oct 30, 2025
Q2
2025
Jun 30, 2024
($33.58M)
Jul 24, 2025
Q1
2025
Mar 31, 2024
($41.52M)
Apr 24, 2025
Q2
2024
Dec 31, 2023
($232.87M)
Jul 25, 2024
Q1
2024
Dec 31, 2023
($232.87M)
May 2, 2024
Q3
2024
Dec 31, 2023
($232.87M)
Oct 30, 2024
Q3
2024
Sep 30, 2023
($58.25M)
Oct 30, 2024
Q2
2024
Jun 30, 2023
($62.66M)
Jul 25, 2024
Q1
2024
Mar 31, 2023
($60.25M)
May 2, 2024
Q3
2023
Dec 31, 2022
($89.52M)
Oct 26, 2023
Q2
2023
Dec 31, 2022
($89.52M)
Jul 27, 2023
Q1
2023
Dec 31, 2022
($89.52M)
May 4, 2023
Q3
2023
Sep 30, 2022
($24.61M)
Oct 26, 2023
Q2
2023
Jun 30, 2022
($21.13M)
Jul 27, 2023